Share

Galera Therapeutics Inc. - news published 108 - readings 1.247

BACK
Galera Therapeutics Inc.

Galera Therapeutics Inc.

Quarterly Report for Quarter Ending March 31, 2024 (Form 10-Q)

10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ ...

Continue reading
13.05.2024
Galera Therapeutics Inc.

Galera Therapeutics Inc.

Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates - Form 8-K

Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates Company's evaluation of potential strategic alternatives progresses with goal to maximize stockholder value MALVERN, Pa. - May 13, 2024 - Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that ha ...

Continue reading
13.05.2024
Galera Therapeutics Inc.

Galera Therapeutics Inc.

Amendment to Statement of Changes in Beneficial Ownership - Form 4/A

Ownership Submission FORM 4/A Check this box if no longer subject to Section 16, Form 4 or Form 5 obligations may continue. See Instruction 1(b). UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investm ...

Continue reading
01.05.2024
Galera Therapeutics Inc.

Galera Therapeutics Inc.

Annual Report for Fiscal Year Ending --12-31, 2023 (Form 10-K)

10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Nu ...

Continue reading
28.03.2024
Galera Therapeutics Inc.

Galera Therapeutics Inc.

Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates - Form 8-K

Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates Company continues to evaluate strategic options to maximize shareholder value MALVERN, Pa. - March 28, 2024 - Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transfor ...

Continue reading
28.03.2024
Galera Therapeutics Inc.

Galera Therapeutics Inc.

Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates

The text version of this document is not available. You can access the original document here . Attachments Original Link Permalink Disclaimer Galera Therapeutics Inc. published this content on 28 March 2024 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 28 March 2024 11:05:29 UTC .

Continue reading
28.03.2024